PL3007694T3 - Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego - Google Patents
Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowegoInfo
- Publication number
- PL3007694T3 PL3007694T3 PL14761286T PL14761286T PL3007694T3 PL 3007694 T3 PL3007694 T3 PL 3007694T3 PL 14761286 T PL14761286 T PL 14761286T PL 14761286 T PL14761286 T PL 14761286T PL 3007694 T3 PL3007694 T3 PL 3007694T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- bladder cancer
- pyrazolopyridine derivatives
- pyrazolopyridine
- derivatives
- Prior art date
Links
- 206010005003 Bladder cancer Diseases 0.000 title 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 201000005112 urinary bladder cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1355578 | 2013-06-14 | ||
| EP14761286.5A EP3007694B1 (en) | 2013-06-14 | 2014-06-13 | Pyrazolopyridine derivatives for use in the treatment of bladder cancer |
| PCT/EP2014/062456 WO2014198942A1 (en) | 2013-06-14 | 2014-06-13 | Pyrazolopyridine derivatives for use in the treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3007694T3 true PL3007694T3 (pl) | 2018-12-31 |
Family
ID=48906407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14761286T PL3007694T3 (pl) | 2013-06-14 | 2014-06-13 | Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9572799B2 (pl) |
| EP (1) | EP3007694B1 (pl) |
| JP (1) | JP2016521721A (pl) |
| KR (1) | KR20160021134A (pl) |
| CN (1) | CN105283184B (pl) |
| AU (1) | AU2014280046B2 (pl) |
| CA (1) | CA2915321A1 (pl) |
| EA (1) | EA030558B1 (pl) |
| ES (1) | ES2691923T3 (pl) |
| MX (1) | MX2015017201A (pl) |
| PL (1) | PL3007694T3 (pl) |
| TR (1) | TR201815333T4 (pl) |
| WO (1) | WO2014198942A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN108774224B (zh) * | 2018-04-23 | 2020-10-30 | 浙江大学 | 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| KR102853551B1 (ko) | 2019-03-19 | 2025-09-02 | 삼성전자주식회사 | 무선 통신 시스템에서 이중 접속을 위한 단말의 상향 채널 전송 방법 및 장치 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114208092B (zh) | 2019-08-08 | 2025-04-15 | 三星电子株式会社 | 用于在无线通信系统中为ue执行双连接的方法和装置 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171765A1 (en) | 2008-11-20 | 2011-07-28 | Genentech Inc | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
-
2014
- 2014-06-13 PL PL14761286T patent/PL3007694T3/pl unknown
- 2014-06-13 TR TR2018/15333T patent/TR201815333T4/tr unknown
- 2014-06-13 US US14/897,929 patent/US9572799B2/en not_active Expired - Fee Related
- 2014-06-13 AU AU2014280046A patent/AU2014280046B2/en not_active Expired - Fee Related
- 2014-06-13 CN CN201480033397.2A patent/CN105283184B/zh not_active Expired - Fee Related
- 2014-06-13 KR KR1020157036036A patent/KR20160021134A/ko not_active Withdrawn
- 2014-06-13 MX MX2015017201A patent/MX2015017201A/es unknown
- 2014-06-13 ES ES14761286.5T patent/ES2691923T3/es active Active
- 2014-06-13 CA CA2915321A patent/CA2915321A1/en not_active Abandoned
- 2014-06-13 WO PCT/EP2014/062456 patent/WO2014198942A1/en not_active Ceased
- 2014-06-13 JP JP2016518522A patent/JP2016521721A/ja active Pending
- 2014-06-13 EA EA201690020A patent/EA030558B1/ru not_active IP Right Cessation
- 2014-06-13 EP EP14761286.5A patent/EP3007694B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EA201690020A1 (ru) | 2016-04-29 |
| AU2014280046B2 (en) | 2019-07-11 |
| WO2014198942A1 (en) | 2014-12-18 |
| AU2014280046A1 (en) | 2016-01-07 |
| MX2015017201A (es) | 2016-04-06 |
| CA2915321A1 (en) | 2014-12-18 |
| US9572799B2 (en) | 2017-02-21 |
| TR201815333T4 (tr) | 2018-11-21 |
| JP2016521721A (ja) | 2016-07-25 |
| CN105283184A (zh) | 2016-01-27 |
| US20160128989A1 (en) | 2016-05-12 |
| EP3007694B1 (en) | 2018-07-18 |
| EP3007694A1 (en) | 2016-04-20 |
| EA030558B1 (ru) | 2018-08-31 |
| CN105283184B (zh) | 2018-01-26 |
| KR20160021134A (ko) | 2016-02-24 |
| ES2691923T3 (es) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3007694T3 (pl) | Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego | |
| IL283943B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders | |
| IL304851A (en) | Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer | |
| IL268094B (en) | History of heterocyclic compounds for use in the treatment of lung cancer | |
| HRP20180876T1 (hr) | Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura | |
| IL246239A0 (en) | Bicyclic heterocyclic compounds and their uses in healing | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL238400A (en) | Triazulophyrazines as brd4 inhibitors for use in cancer treatment | |
| SG11201702611YA (en) | Combination therapy for use in cancer therapy | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| PT3004108T (pt) | Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| IL233493A (en) | Imidazopyridine derivatives for cancer treatment | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| ZA201508530B (en) | Pyrazolopyridine derivatives for use in the treatment of bladder cancer | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| GB201322755D0 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment |